May 19, 2016 — BioVentrix announced the first-in-man use of its next-generation Revivent-TC System with an endovascular catheter-based approach from within the left ventricle. The Less Invasive Ventricular Enhancement (LIVE) procedure, used to reshape and reduce the left ventricle (LV), now utilizes deployment of its micro-anchor technology to exclude scar tissue from within the vasculature and without opening the chest. The device was successfully implanted in a 64-year-old female patient suffering from heart failure symptoms as a result of a myocardial infarction.
The procedure was performed by Dr. med. Giedrius Davidavicius, interventional cardiologist, and Dr. med. Gintaras Kalinauskas, cardiothoracic surgeon, at Vilnius University Hospital in Vilnius, Lithuania.
"We are very pleased with the results of the Revivent-TC endovascular delivery system and the immediate clinical benefit to the patient," said Davidavicius. "This new endovascular delivery system to exclude the scar from within the LV cavity reduces procedural risk, improves accuracy of anchor implant and enables a more minimally invasive approach for patients suffering from this disease."
"For patients this fragile, they are often precluded from any meaningful intervention due to the risks and extended recovery," said Kalinauskas. "The new Revivent-TC endovascular approach has provided an opportunity for more patients who are suffering from ischemic cardiomyopathy to be treated; while the improved accuracy of anchor placement should lead to even better clinical outcomes for these patients," continued Kalinauskas.
BioVentrix has shown that the exclusion of scar tissue from the LV cavity in patients suffering from ischemic cardiomyopathy heart failure results in substantial improvements in quality of life. Additionally, previous studies reported in the surgical literature have shown that a significant LV volume reduction conveys a survival benefit for treated patients.
For more information: www.bioventrix.com
April 24, 2024 
